• Citer

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

par Rodón, Jordi;Tan, Daniel Shao Weng;Garrido-Laguna, Ignacio;Harb, Wael W.A.;Bessudo, Alberto;Beck, Joseph Thaddeus;Rottey, Sylvie;Bahary, Nathan;Kotecki, Nuria;Zhu, Zhou;Deng, Shibing;Kowalski, Karey;Wei, Caimiao;Pathan, Nuzhat;Laliberte, Robert ;Messersmith, Wells
Référence ESMO Open, 8, 4, 101584
Publication Publié, 2023-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial
Auteur:	Rodón, Jordi; Tan, Daniel Shao Weng; Garrido-Laguna, Ignacio; Harb, Wael W.A.; Bessudo, Alberto; Beck, Joseph Thaddeus; Rottey, Sylvie; Bahary, Nathan; Kotecki, Nuria; Zhu, Zhou; Deng, Shibing; Kowalski, Karey; Wei, Caimiao; Pathan, Nuzhat; Laliberte, Robert; Messersmith, Wells
Informations sur la publication:	ESMO Open, 8, 4, 101584
Statut de publication:	Publié, 2023-08
Sujet CREF:	Sciences biomédicales
Mots-clés:	immune checkpoint inhibitor
	MEK inhibitor
	metastatic pancreatic ductal adenocarcinoma
	PARP inhibitor
	PD-L1
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2059-7029
	info:doi/10.1016/j.esmoop.2023.101584
	info:pii/S2059702923008177
	info:scp/85162901749
	info:pmid/37379764